NeuroRX

, Volume 1, Issue 2, pp 226–234

Biomarkers of Alzheimer disease in plasma

Article

DOI: 10.1602/neurorx.1.2.226

Cite this article as:
Irizarry, M.C. Neurotherapeutics (2004) 1: 226. doi:10.1602/neurorx.1.2.226

Summary

Plasma and serum biochemical markers proposed for Alzheimer disease (AD) are based on pathophysiologic processes such as amyloid plaque formation [amyloid β-protein (Aβ), Aβ autoantibodies, platelet amyloid precursor protein (APP) isoforms], inflammation (cytokines), oxidative stress (vitamin E, isoprostanes), lipid metabolism (apolipoprotein E, 24S-hydroxycholesterol), and vascular disease [homocysteine, lipoprotein (a)]. Most proteins or metabolites evaluated in plasma or serum thus far are, at best, biological correlates of AD: levels are statistically different in AD versus controls in some cohorts, but they lack sensitivity or specificity for diagnosis or for tracking response to therapy. Approaches combining panels of existing biomarkers or surveying the range of proteins in plasma (proteomics) show promise for discovering biomarker profiles that are characteristic of AD, yet distinct from nondemented patients or patients with other forms of dementia.

Key Words

Biomarkersamyloid β-proteinisoprostaneshomocysteine24S-hydroxycholesterolcytokinesproteomics

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2004

Authors and Affiliations

  1. 1.Alzheimer Disease Research Unit, Department of NeurologyMassachusetts General HospitalCharlestown